Merck & Co (MRK)

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry...

Investors buying this biotech stock now will get its pipeline essentially for free.

Over the past six months, Merck has been a great trade, beating the S&P 500 by 13.4%. Its stock price has climbed to $149.98, representing a healthy 29.6% in...

BioNTech's recent pipeline setback is a real cause of concern. But investors shouldn't panic.

Long-term holders of the Schwab U.S. Dividend Equity ETF have seen their yield on cost gradually rise.

Merck & Co., Inc. (NYSE:MRK) Chairman and CEO Rob Davis said the company’s “transformation is underway,” citing progress across product launches, clinical data readouts, business development and its Animal Health segment during a Morgan Stanley discussion. Davis said recent pipeline readouts ha

The biotech is entering a new era.

Coca-Cola, Chevron, and Merck have outperformed the S&P 500 in 2026, each pairing strong share-price gains with growing dividends backed by solid fundamentals.

Income seekers can't go wrong with these companies.

During bear markets and recessions, it's good to be invested in "defensive" stocks and funds that hold up better than average.

September 9, 2026 records indicate that Representative Maria Elvira Salazar filed a purchase of Merck & Co (NYSE:MRK), valued between $34,006 and $160,000. According to the September filing, the transaction occurred